N-(4-(4-(6-amino-5-methoxypyridin-3-yl)-2-phenyl-1H-imidazol-5-yl)pyridin-2-yl)acetamide | 1188299-55-9

• 分子结构分类: 有机化合物
• 英文名称: N-(4-(4-(6-amino-5-methoxypyridin-3-yl)-2-phenyl-1H-imidazol-5-yl)pyridin-2-yl)acetamide
• 英文别名: N-[4-[4-(6-amino-5-methoxypyridin-3-yl)-2-phenyl-1H-imidazol-5-yl]pyridin-2-yl]acetamide
• CAS: 1188299-55-9
• 化学式: C₂₂H₂₀N₆O₂
• 分子量: 400.44
• InChiKey: RSKSKWAYHSBEQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Novel Heterocyclic Compounds and Uses Thereof
  申请人：Huang Zilin

  公开号：US20130210818A1

  公开（公告）日：2013-08-15

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代杂环化合物，含有它们的组合物，以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。
• Novel heterocyclic compounds and uses therof
  申请人：Hunag Zilin

  公开号：US20100003246A1

  公开（公告）日：2010-01-07

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本文提供了新的取代杂环化合物、含有它们的组合物以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• US8129394B2
  申请人：——

  公开号：US8129394B2

  公开（公告）日：2012-03-06
• US8865732B2
  申请人：——

  公开号：US8865732B2

  公开（公告）日：2014-10-21
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2009115572A2

  公开（公告）日：2009-09-24

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.